GC
WINT

Guggenheim Capital’s Windtree Therapeutics Inc WINT Stock Holding History

Guggenheim Capital’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-941
Closed -$4K – 3137
2015
Q3 		$4K Buy
941
+118
+14% +$781 ﹤0.01% 2949
2015
Q2 		$8K Hold
823
– – ﹤0.01% 3024
2015
Q1 		$14K Buy
823
+3
+0.4% +$59 ﹤0.01% 3011
2014
Q4 		$13K Buy
+820
New +$18K ﹤0.01% 2985
2014
Q3 		– Sell
-2,775
Closed -$69K – 3212
2014
Q2 		$69K Sell
2,775
-27,401
-91% -$700K ﹤0.01% 3044
2014
Q1 		$908K Sell
30,176
-4,303
-12% -$145K ﹤0.01% 2316
2013
Q4 		$1.09M Sell
34,479
-169
-0.5% -$5.29K ﹤0.01% 2195
2013
Q3 		$951K Buy
34,648
+12
+0% +$291 ﹤0.01% 2124
2013
Q2 		$737K Buy
+34,636
New +$853K ﹤0.01% 2231

Other funds holding WINT

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Guggenheim Capital's WINT Position: Q4 2015 in Review

Guggenheim Capital sold out of Windtree Therapeutics Inc (WINT) in Q4 2015, closing a stake of 941 shares — an estimated $4K sold.

Guggenheim Capital first reported a position in WINT in Q2 2013 and held it in 9 quarters. The position peaked at $1.09M in Q4 2013. 53 funds tracked by Wall St. Rank hold WINT as of Q4 2015.

  • Guggenheim Capital reported no remaining Windtree Therapeutics Inc position as of Q4 2015 after selling out during the quarter.
  • Guggenheim Capital sold 941 Windtree Therapeutics Inc shares in Q4 2015, an estimated $4K.
  • Guggenheim Capital first reported a position in Windtree Therapeutics Inc in Q2 2013 and held it in 9 quarters.
  • Guggenheim Capital's Windtree Therapeutics Inc position peaked at $1.09M in Q4 2013.
  • 53 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q4 2015.

Based on Guggenheim Capital's 13F filing for Q4 2015, filed 16 Feb 2016.